CLINICAL_TRIALS
trial_result
· 2014-08-08
Clinical Trial Update: A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma. [Phase 2]
Summary
A Phase 2 study evaluating MabThera (rituximab) in primary central nervous system lymphoma was terminated. Results were posted in 2014.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Hoffmann-La Roche | Conditions: Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2014-08-08